Back to top
more

QuidelOrtho (QDEL)

(Delayed Data from NSDQ)

$42.82 USD

42.82
672,309

-1.17 (-2.66%)

Updated May 17, 2024 04:00 PM ET

After-Market: $42.83 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks.com featured expert Kevin Matras highlights: Lululemon Athletica, Quidel, Kirkland Lake Gold and World Wrestling Entertainment

by Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Lululemon Athletica, Quidel, Kirkland Lake Gold and World Wrestling Entertainment

Tirthankar Chakraborty headshot

4 Must-Buy Efficient Stocks for Your Portfolio

by Tirthankar Chakraborty

A company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with the company's price performance.

Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.

Quidel (QDEL) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Quidel (QDEL) delivered earnings and revenue surprises of 29.03% and 0.32%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Quidel (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.

Here's Why You Should Buy Express Scripts (ESRX) Stock Now

by Zacks Equity Research

Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.

Here's Why You Should Hold Allscripts Stock in Your Portfolio

by Zacks Equity Research

Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.

Express Scripts Announces 3-Year Agreement With Walmart

by Zacks Equity Research

Express Scripts (ESRX) and Walmart (WMT) collaborate to increase affordable access of the expensive prescription drugs for insured and uninsured patients.

Quidel (QDEL) Catches Eye: Stock Jumps 6.7%

by Zacks Equity Research

Quidel (QDEL) shares rose nearly 7% in the last trading session, amid huge volumes.

BD Gets Enterprise Level Cybersecurity Assessment From UL

by Zacks Equity Research

BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.

Here's Why Investors Should Hold Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) gains from solid prospects in the SET Pulse Oximeter platform. However, cutthroat competition in the MedTech space is likely to hurt the stock.

Ecolab to Boost Food Safety Standards With Holchem Buyout

by Zacks Equity Research

Ecolab (ECL) to benefit from Holchem Group's unique offerings for the food and beverage, foodservice and hospitality industries.

Here's Why Investors Should Hold AngioDynamics Stock Now

by Zacks Equity Research

AngioDynamics' (ANGO) gains from solid prospects in the NanoKnife platform. However, sluggishness in the Venous Insufficiency business is a headwind.

Veeva Systems Announces New DAM Solution for Life Sciences

by Zacks Equity Research

Veeva Vault Digital Publishing uses Veeva Systems' (VEEV) flagship Vault PromoMats or Vault MedComms platforms for updating digital content. The platform leverages on Amazon CloudFront.

Here's Why You Should Hold Pacific Biosciences (PACB) Now

by Zacks Equity Research

Pacific Biosciences (PACB) is likely to gain from strong prospects in the Sequel System platform. However, the company faces cutthroat competition in the DNA sequencing market.

Here's Why You Should Invest in Accuray (ARAY) Stock Now

by Zacks Equity Research

Accuray's (ARAY) benefits from growing adoption of non-surgical treatment options among cancer patients and increasing demand for its latest offerings.

    Ecolab to Buy Bioquell for Healthcare & Life Sciences' Growth

    by Zacks Equity Research

    Ecolab (ECL) to leverage on Bioquell's innovative bio-decontamination and isolator platforms for residue-free surface decontamination.

    Cardinal Health to Highlight Cost-Control Approach in ASHP

    by Zacks Equity Research

    Cardinal Health (CAH) helps hospitals identify hidden savings, improve patient outcomes and drive supply chain efficiencies.

    Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel

    by Zacks Equity Research

    Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel

    Here's Why Investors Should Hold Medidata (MDSO) Stock Now

    by Zacks Equity Research

    Solid prospects in the Rave Genomics platform are likely to provide Medidata (MDSO) a competitive edge in the MedTech space.

    4 Profitable Stocks Boasting Amazingly High Net Income Ratio

    by Zacks Equity Research

    Profitability analysis is considered one of the best possible ways to assess the prospects of a company.

    Quidel (QDEL) Surpasses Q3 Earnings Estimates

    by Zacks Equity Research

    Quidel (QDEL) delivered earnings and revenue surprises of 18.00% and -2.72%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.

    What's in the Offing for DaVita (DVA) This Earnings Season?

    by Zacks Equity Research

    DaVita (DVA) likely to gain from its Kidney Care wing. However, DaVita RX and GranuFlo units are likely to disappoint.